Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus.

Literature DB >> 17103330

Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus.

N Hamaue¹, A Ogata, M Terado, K Ohno, S Kikuchi, H Sasaki, K Tashiro, M Hirafuji, M Minami.

Abstract

We analyzed two disease model groups with rats infected by Japanese encephalitis virus (JEV), a 90-day group and a 180-day group after JEV infection. The time measured by the modified pole test showed that motor activities in these two groups were slower than those of age-matched control groups. Striatal dopamine (DA) levels were significantly decreased in all JEV-infected rats. Norepinephrine concentration in brain regions in the 180-day group was significantly decreased in the medulla oblongata and hypothalamus as compared with the control and 90-day group. Tyrosine hydroxylase-positive neurons were significantly decreased in both JEV-infected rat groups. These results suggest that DA decrease and pathological changes in JEV-infected model rats persist for a long time, at least up to 180 days, and this model will be useful for the evaluation of new anti-parkinsonian agents.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2006 PMID： 17103330 DOI： 10.1007/s11064-006-9197-5

Source DB: PubMed Journal: Neurochem Res ISSN： 0364-3190 Impact factor: 3.996

13 in total

1. Protein measurement with the Folin phenol reagent.

Authors: O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal: J Biol Chem Date: 1951-11 Impact factor: 5.157

2. Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus.

Authors: Akihiko Ogata; Naoya Hamaue; Mutsuko Terado; Masaru Minami; Kazuo Nagashima; Kunio Tashiro
Journal: J Neurol Sci Date: 2003-01-15 Impact factor: 3.181

3. Japanese encephalitis and parkinsonism.

Authors: H Shoji; M Watanabe; S Itoh; H Kuwahara; F Hattori
Journal: J Neurol Date: 1993-01 Impact factor: 4.849

4. Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis.

Authors: S Pradhan; N Pandey; S Shashank; R K Gupta; A Mathur
Journal: Neurology Date: 1999-11-10 Impact factor: 9.910

5. A rat model of Parkinson's disease induced by Japanese encephalitis virus.

Authors: A Ogata; K Tashiro; S Nukuzuma; K Nagashima; W W Hall
Journal: J Neurovirol Date: 1997-04 Impact factor: 2.643

6. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus.

Authors: F Shintani; S Kanba; T Nakaki; M Nibuya; N Kinoshita; E Suzuki; G Yagi; R Kato; M Asai
Journal: J Neurosci Date: 1993-08 Impact factor: 6.167

7. Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes.

Authors: H Tohgi; T Abe; S Takahashi; J Takahashi; Y Nozaki; M Ueno; T Kikuchi
Journal: J Neural Transm Park Dis Dement Sect Date: 1993

8. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.

Authors: P A Ballard; J W Tetrud; J W Langston
Journal: Neurology Date: 1985-07 Impact factor: 9.910

9. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease.

Authors: M Riekkinen; K Kejonen; P Jäkälä; H Soininen; P Riekkinen
Journal: Eur J Neurosci Date: 1998-04 Impact factor: 3.386

10. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain.

Authors: J Glowinski; L L Iversen
Journal: J Neurochem Date: 1966-08 Impact factor: 5.372

14 in total

Review 1. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors: Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal: Neurotox Res Date: 2011-10-15 Impact factor: 3.911

Review 2. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors: Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal: Exp Neurol Date: 2007-07-17 Impact factor: 5.330

3. Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease.

Authors: Deborah Ariza; Marcelo M S Lima; Camila G Moreira; Patrícia A Dombrowski; Thiago V Avila; Alexandra Allemand; Daniel A G B Mendes; Claudio Da Cunha; Maria A B F Vital
Journal: Neurochem Res Date: 2010-06-26 Impact factor: 3.996

Review 4. Viral parkinsonism.

Authors: Haeman Jang; David A Boltz; Robert G Webster; Richard Jay Smeyne
Journal: Biochim Biophys Acta Date: 2008-08-12

5. Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases.

Authors: David S Goldstein; LaToya Sewell
Journal: Parkinsonism Relat Disord Date: 2009-02-07 Impact factor: 4.891

Review 6. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.

Authors: Garima Dutta; Ping Zhang; Bin Liu
Journal: Fundam Clin Pharmacol Date: 2008-08-15 Impact factor: 2.748

Review 7. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Authors: Malú G Tansey; Matthew S Goldberg
Journal: Neurobiol Dis Date: 2009-11-10 Impact factor: 5.996